INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $569,902 | +76.9% | 30,739 | +5.5% | 0.00% | – |
Q2 2023 | $322,168 | +44.2% | 29,129 | +75.1% | 0.00% | – |
Q1 2023 | $223,369 | +43.9% | 16,632 | +32.5% | 0.00% | – |
Q4 2022 | $155,219 | +9.3% | 12,548 | +23.6% | 0.00% | – |
Q3 2022 | $142,000 | +8.4% | 10,148 | +7.2% | 0.00% | – |
Q2 2022 | $131,000 | -25.6% | 9,468 | -12.6% | 0.00% | – |
Q1 2022 | $176,000 | 0.0% | 10,834 | 0.0% | 0.00% | – |
Q4 2021 | $176,000 | +6.7% | 10,834 | -2.7% | 0.00% | – |
Q3 2021 | $165,000 | -45.9% | 11,132 | -27.2% | 0.00% | – |
Q2 2021 | $305,000 | -11.6% | 15,288 | +2.3% | 0.00% | – |
Q1 2021 | $345,000 | -6.8% | 14,949 | -0.2% | 0.00% | – |
Q4 2020 | $370,000 | -40.5% | 14,983 | -0.3% | 0.00% | – |
Q3 2020 | $622,000 | -19.6% | 15,025 | -7.0% | 0.00% | – |
Q2 2020 | $774,000 | -12.2% | 16,154 | +15.3% | 0.00% | -100.0% |
Q1 2020 | $882,000 | -53.2% | 14,011 | -8.0% | 0.00% | 0.0% |
Q4 2019 | $1,886,000 | +100.0% | 15,224 | +7.1% | 0.00% | – |
Q3 2019 | $943,000 | +13.6% | 14,219 | +36.3% | 0.00% | – |
Q2 2019 | $830,000 | -21.8% | 10,432 | +9.8% | 0.00% | -100.0% |
Q1 2019 | $1,062,000 | +13.1% | 9,497 | +2.0% | 0.00% | 0.0% |
Q4 2018 | $939,000 | -16.0% | 9,313 | +5.2% | 0.00% | 0.0% |
Q3 2018 | $1,118,000 | +97.2% | 8,849 | +30.8% | 0.00% | – |
Q2 2018 | $567,000 | +0.4% | 6,763 | -26.4% | 0.00% | – |
Q1 2018 | $565,000 | +9.1% | 9,193 | +3.8% | 0.00% | – |
Q4 2017 | $518,000 | +0.8% | 8,856 | 0.0% | 0.00% | – |
Q3 2017 | $514,000 | -28.9% | 8,856 | +48.2% | 0.00% | -100.0% |
Q2 2017 | $723,000 | +18.1% | 5,974 | +10.4% | 0.00% | 0.0% |
Q1 2017 | $612,000 | +207.5% | 5,413 | +196.6% | 0.00% | – |
Q4 2016 | $199,000 | +1.5% | 1,825 | +52.6% | 0.00% | – |
Q3 2016 | $196,000 | +14.6% | 1,196 | 0.0% | 0.00% | – |
Q2 2016 | $171,000 | +16.3% | 1,196 | +4.5% | 0.00% | – |
Q1 2016 | $147,000 | -0.7% | 1,144 | +15.8% | 0.00% | – |
Q4 2015 | $148,000 | +18.4% | 988 | +31.4% | 0.00% | – |
Q3 2015 | $125,000 | -20.4% | 752 | +15.7% | 0.00% | – |
Q2 2015 | $157,000 | +21.7% | 650 | +42.5% | 0.00% | – |
Q1 2015 | $129,000 | – | 456 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $39,083,000 | 9.04% |
Senvest Management, LLC | 1,152,032 | $70,873,000 | 5.40% |
Melqart Asset Management (UK) Ltd | 298,200 | $18,345,000 | 2.20% |
Elk Creek Partners, LLC | 348,454 | $21,437,000 | 1.25% |
ALTRINSIC GLOBAL ADVISORS LLC | 375,223 | $23,084,000 | 0.93% |
BB BIOTECH AG | 545,719 | $33,573,000 | 0.93% |
Virtus ETF Advisers LLC | 14,681 | $903,000 | 0.78% |
Opus Point Partners Management, LLC | 4,496 | $277,000 | 0.54% |
Spark Investment Management LLC | 136,500 | $8,397,000 | 0.54% |
Regal Investment Advisors LLC | 29,511 | $1,816,000 | 0.40% |